Blue Horseshoe Stocks: TRXC Recap & Much More

TransEnterix Inc. TRXC

TRXC stood out among the other mentions in Friday’s premarket report. Following our tag of this stock it shot quite rapidly from an early low of 2.73, and reached a subsequent high of 4.05 shortly after 11AM EST.

We want to congratulate any of our reader who were able to take advantage of that timely alert which yielded the opportunity at intraday gains of up to 48%  The healthy spike came on nearly tenfold the 3-month average trading volume.

Friday’s move came in conjunction with the announcement of successful pre-clinical trials for its SurgiBot minimally invasive surgery system. Two different doctors used TRXC’s product in actual medical procedures and subsequently offered their endorsements. It is an important step on the way to FDA application submission, which the company has stated should be on the table by mid-2015. Thus, TRXC may be one that we’ll want to have on a more long-term watch.

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery, today announced the successful completion of four general surgery and urology procedures using its SurgiBot system patient-side robotic surgery system. >> FULL PR


The First Marblehead Corp. FMD

We also wanted to give a quick nod to FMD for a solid performance following its inclusion in Friday morning’s watchlist. The stock found a low of 4.65 within the first several minutes of the open, and would go on to end the day with a on a high note, reaching as high as 5.35 and marking a respectable intraday move of 15%


Nuvilex, Inc. NVLX

Our first mention of NVLX dates all way back to August of 2013 when we released a special report on the company and its pancreatic cancer treatment, which at the time was in the early stages of Phase-2 trials. (Read the Special Report HERE)

A major development hit the presswires this morning regarding the FDA’s granting of ‘Orphan Drug’ status to that treatment, so we wanted to bring the stock back into the mix.

It’s coming off of a recent bottom as well, so NVLX is certainly going to be reserved a spot on our watchlist as the story continues to play out. The company has stated that Phase-3 trials should begin in 2015.

SILVER SPRING, Md., Dec. 22, 2014 (GLOBE NEWSWIRE) — Nuvilex, Inc. (NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Nuvilex orphan drug designation for its pancreatic cancer treatment. >> FULL PR


Rite-Aid Corp. RAD

We tagged RAD for tracking this past Tuesday, and the stock responded with a respectable performance on the week. An earnings beat as well as heightened guidance facilitated a healthy move from a low of 5.73 to a subsequent high of 7.05, marking a 23% intraweek spike.


Extended Watchlist:
GSS(Bottom Bouncer coming off 52-week lows), CANF, APP, TGE, ACHN

Blue Horseshoe Stocks: HUGE News in the Marijuana Industry

Medical/Legal Marijuana Sector Set to Explode

If that headline seems a little sensationalistic, that’s because something sensational has happened! Many of you will recall our continuous coverage of marijuana-related stocks beginning last year, as Washington and Colorado were getting ready to vote on becoming the first states to end more than seven decades of marijuana prohibition. The prospect of companies legally being able to cash in on what is most assuredly a multi-billion dollar industry just waiting to be unlocked, was and still is, quite exciting.

We rode several hemp stocks (which we’ll mention below) to astonishing gains, and have been continuously tracking the landscape of this burgeoning market sector ever since. Even with such progress being made in legislation, as well as a positive general shift in public opinion on the subject, we still had to temper our enthusiasm. The federal government had not yet taken an official position on the issue of whether or not it would intervene in the rights of individual states to grant their citizens access to legal marijuana. And so the nation, including several other states with legalization ambitions of their own, waited for news of their ultimate fate.

Then yesterday came… In the future, Thursday, August 29th, 2013, could very well be viewed as a turning point in the fight against marijuana prohibition. The US Department of Justice finally announced their official position: The federal government WILL NOT interfere with individual states who wish to legalize, regulate, and tax marijuana for both medical and personal recreational use. The door to a pot industry boom has just been unlocked, and left wide open.

In the wake of this historic event, we thought there would be no better time to remind our readers that this was one of the main reasons we’ve been so “high” on marijuana stocks for over a year now. It is rare to witness the birth of an entire industry, and yet it seems this baby has finally arrived! Check out the enormous list of related stocks below that have appeared in previous reports (I, II, III, IV) and be sure to keep them on your radars moving forward, as a world of possibilities (without fear of federal reprisal) has just opened up for the entire sector.

HEMP, PHOT, MJNA, CBIS, RFMK, ERBB, GRNH, MDBX, MWIP, TRTC, RIGH, EXMT, EDXC, SKTO, FSPM, NRBT, GTLA, GWPRF, HESG, PARS, SRER, SFIO, XCHC & NVLX.

We’ll also be on the lookout for new marijuana related stocks, which are likely to start sprouting up like weeds now that the federal green light has been given. More on the subject is sure to come, so stay tuned to our daily reports, and good luck out there!

Blue Horseshoes Stocks: Afternoon Update

Nuvilex, Inc. NVLX

NVLX, after starting off the day as low as .125, is testing new highs this afternoon, having just touched a high of .1425 for a 14% intraday increase.

A quick look at the chart shows the stock broke above the 50DMA, a good sign, and the RSI is trying to  get back above the 50-line. We’re also on the lookout for a bullish MACD cross, as we pointed out in the NVLX video chart,which was featured in yesterday’s NVLX Special Report.


IceWEB, Inc. IWEB

IWEB opened as low as .0324 this morning, and managed a high of .038 (+17%). We then saw a dip back to .034, and currently it’s trading back at the .0355 level. So all in all, we seen some nice price action from IWEB today, including those intraday moves which amount the possibility of up to 21% in cumulative gains on the day.

In total, IWEB has brought us the opportunity at well over 300% in gains since we initiated coverage back on July 9th.

We’ll also add that the BARCHART.COM Opinion on IWEB still reads green, to the tune of a 72% Overall “Buy” Rating.